We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FORA:NASDAQForian Inc. Analysis

Data as of 2026-05-20 - not real-time

$2.17

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Forian Inc. (FORA) is trading at $2.17, just below the identified resistance level of $2.18 and above the support of $2.15, with the 20‑day SMA (2.16) sitting above both the 50‑day (2.12) and 200‑day (2.13) averages, suggesting a modest short‑term upside bias. However, the MACD histogram is negative and the MACD line trails its signal, delivering a bearish signal, while the RSI of 64 hints at nearing overbought territory. Fundamentally, the stock appears undervalued – the DCF‑derived fair value of $2.73 exceeds the current price, and the forward P/E of 24.1 is below the industry average of 27.2 – yet the company reports negative operating margins, a -2.9% revenue decline, and a trailing EPS of -$0.09, offset by a strong cash position ($30.9 M) and negligible debt.
The most material recent events are the completion of a tender offer and pending delisting from Nasdaq, coupled with a shareholder‑alerted investigation, both of which heighten legal and liquidity risks. Investors should weigh the upside implied by valuation metrics against the uncertainty from corporate restructuring and potential regulatory scrutiny.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price at resistance with bearish MACD
  • Ongoing legal investigation
  • Impending delisting reducing marketability

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • DCF fair value suggests upside potential
  • Strong cash balance and minimal debt
  • Uncertainty from corporate restructuring

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Sector tailwinds for health data services
  • Potential strategic repositioning under new ownership
  • Undervalued relative to peer multiples

Key Metrics & Analysis

Financial Health

Revenue Growth-2.90%
Profit Margin-17.00%
P/E Ratio24.1
ROE-17.95%
ROA-8.37%
Debt/Equity0.02
P/B Ratio2.3
Op. Cash Flow$1.9M
Free Cash Flow$4.2M
Industry P/E27.2

Technical Analysis

TrendNeutral
RSI64.0
Support$2.15
Resistance$2.18
MA 20$2.16
MA 50$2.12
MA 200$2.13
MACDBearish
VolumeStable
Fear & Greed Index89.18

Valuation

Fair Value$2.73
GradeUndervalued
TypeValue

Risk Assessment

Beta0.36
Volatility8.44%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.